IOBT - IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Benzinga
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in the perioperative setting in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) will be presented.
"We are committed to investigating the use of IO102-IO103 combined with PD-1 inhibitors to treat various types of cancer, including melanoma, lung cancer and head and neck cancer," said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. "The IOB-032 Phase 2 study is designed to provide us with insights into treatment outcomes in earlier disease settings with neoadjuvant and adjuvant treatment of patients with melanoma and SCCHN and we look forward to the results of this trial."
Presentation Details
Title: A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors
Abstract Number: TPS2701
Presenter: Georgina V. Long
Date: June 1, 2024
Location and time: 9:00 AM - 12:00 PM CDT
About IOB-032/PN-E40
IOB-032/PN-E40 (NCT05280314) is a Phase 2 basket trial investigating the IO102-IO103 therapeutic cancer vaccine in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. The ...